Evidence map›Paper›PMID 41118244›Full record

ArticleEpilepsia2026

C1q neutralization during epileptogenesis attenuates complement-mediated synaptic elimination and epileptiform activity.

Yoonyi Jeong, Hyun-Kyoung Lim, Hayeon Kim, Juheon Lee, Siyoon Lee, Minah Suh

Abstract read
In one paragraph

Article in Epilepsia, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
  9. Review
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Yoonyi JeongDepartment of Biomedical Engineering, Sungkyunkwan University, Suwon, Republic of Korea.ORCID https://orcid.org/0000-0002-0273-0133
Hyun-Kyoung LimCenter for Neuroscience Imaging Research, Institute for Basic Science, Suwon, Republic of Korea.ORCID https://orcid.org/0000-0003-1818-420X
Hayeon KimDepartment of Biomedical Engineering, Sungkyunkwan University, Suwon, Republic of Korea.ORCID https://orcid.org/0009-0000-3147-2615
Juheon LeeDepartment of Biomedical Engineering, Sungkyunkwan University, Suwon, Republic of Korea.ORCID https://orcid.org/0000-0002-4241-0337
Siyoon LeeDepartment of Biomedical Engineering, Sungkyunkwan University, Suwon, Republic of Korea.ORCID https://orcid.org/0009-0005-4300-7055
Minah SuhDepartment of Biomedical Engineering, Sungkyunkwan University, Suwon, Republic of Korea.ORCID https://orcid.org/0000-0002-1393-3550

Funding

Institute for Basic Science IBS-R015-D1Institute for Basic Science IBS-R015-D2Institute of Information & Communications Technology Planning & Evaluation 2020-0-00261National Research Foundation of Korea 2017R1A6A1A03015642National Research Foundation of Korea 2023R1A2C1004318the Fourth Stage of the Brain Korea 21 Project in the Department of Intelligent Precision Healthcare RS-2022-0608-000
6 · The paper itself

Abstract

objectiveAccumulating evidence indicates that aberrant C1q-C3 complement signaling in microglia and astrocytes drives synaptic dysfunction and neuronal loss. C1q-mediated synaptic dysfunction disrupts neuronal circuitry balance and can lead to network hyperexcitability in epilepsy. However, the therapeutic potential of C1q inhibition remains unclear. This study aimed to delineate whether blocking C1q-driven pathways at critical times can effectively prevent further synaptic loss and attenuate epileptiform activity in a mouse model of epilepsy.

methodsMicroglial C1q and astrocytic C3 expression was examined in hippocampal CA1 and CA3 regions at acute (1 day), subacute (7, 14 days), and chronic (5 weeks) phases following pilocarpine-induced status epilepticus (SE) in mice. To evaluate the role of C1q activation, a C1q-neutralizing antibody or isotype control immunoglobulin G antibody was administered into cisterna magna at 7 days post-SE. During the chronic phase, glial reactivity, dendritic spine density, and epileptiform activity were assessed by immunostaining, Golgi staining, and electroencephalography (EEG) recording. After exclusions, 58 mice were included in the study.

resultsC1q expression was elevated during the subacute phase (7 and 14 days post-SE) in CA1 and CA3 regions; astrocytic C3 expression increased in CA1 and persisted chronically. C1q-neutralizing antibody administration at 7 days post-SE, a time point characterized by prominent C1q upregulation, attenuated microglial synaptic phagocytosis, and astrocytic C3 activation. This intervention preserved dendritic spine density and ultimately reduced interictal spike frequency in EEG recordings in the chronic phase. SIGNIFICANCE: Our findings demonstrate that C1q acts as an upstream mediator of complement-driven neuronal loss during epileptogenesis. C1q blockade interrupted the pathogenic cascade involving microglial engulfment and astrocytic C3 upregulation, thereby preserving synaptic and neuronal integrity and reducing interictal spike activity. Our study highlights the therapeutic potential of C1q inhibition, which can provide multifaceted benefits by mitigating neuroinflammation, improving synaptic integrity, and reducing epileptiform activity during epileptogenesis.

Indexed as

Antibodies, NeutralizingComplement C1qEpilepsyStatus EpilepticusSynapsesAnimalsAstrocytesComplement C3Disease Models, AnimalElectroencephalographyHippocampusMaleMiceMice, Inbred C57BLMicrogliaPilocarpineAntibodies, NeutralizingComplement C1qComplement C3PilocarpineC1qdendritic spinesepileptogenesismicrogliaphagocytosis

Identifiers

PMID41118244
PMCPMC12927691

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.